Search for: "PHASE INC" Results 281 - 300 of 2,475
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Jul 2021, 2:03 pm by Stuart Kaplow
I. du Pont de Nemours and Company, The Chemours Company, DuPont de Nemours, Inc. and Corteva, Inc. [read post]
11 Jul 2021, 5:20 am by Kevin LaCroix
On January 21, 2021, Acmar completed a merger with CarLotz, Inc. [read post]
29 Jun 2021, 4:00 am by Deanne Sowter
On March 1, 2021, the long-awaited amendments to the Divorce Act, RSC 1985 c3 (2nd Supp) came into effect, changing the word “custody” to the more accurate “decision-making”, expanding on the best interests of the child test, creating presumptions for relocation, and for the first time, recognizing family violence. [read post]
28 Jun 2021, 8:53 am by Jason Shinn
Thanoo’s new employer, Aurobindo Pharma U.S.A., Inc., and its parent and affiliated companies (collectively Defendants). [read post]
24 Jun 2021, 10:25 am by Daily Record Staff
Gaithersburg-based biopharmaceutical company Sirnaomics Inc. announced it has begun dose administration for the first patient in a Phase 1 U.S. clinical study for liver cancer treatment. [read post]
13 Jun 2021, 4:54 pm by INFORRM
Competition and Markets Authority over its plan to phase out cookies via its Privacy Sandbox proposal, Adweek reports. [read post]
6 Jun 2021, 10:16 pm by Javier Dominguez
Now in the discovery phase, the case is set for trial in January 2022 after surviving a motion to dismiss in 2020. [read post]
1 Jun 2021, 12:14 pm by Rohini Kurup
Event Announcements (More details on the Events Calendar) Tuesday, June 1, 2021, at 12:00 p.m.: The Freeman Spogli Institute for International Relations at Stanford will host a panel discussion on government reshaping of norms and practices to constrain online activity in the Middle East. [read post]
14 May 2021, 6:00 am by Monica Williamson
United South & Eastern Tribes, Inc. [read post]
26 Apr 2021, 11:08 am by Daily Record Staff
Sirnaomics, Inc., a Gaithersburg-based biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, Monday announced the initiation of the Phase 2b study of the company’s lead drug candidate, STP705, for the treatment of squamous cell skin cancer. [read post]